For how we live.
Across 1463 patients at 49 centres, 13% died of Cushing-related causes and 43% died overall. Reaching biochemical remission within six months roughly halved the risk of those deaths.
The patented method uses mifepristone for hypercortisolism-related insulin resistance, with dosing capped to avoid over-activating the stress-hormone axis. The public can object before the deal closes.
Relacorilant kept blood pressure under control when patients who had responded were kept on it rather than switched to placebo. The pivotal trial randomised just 62 people.